For instance, anti-PD-1 antibody produced objective responses only in approximately one in four to one in five patients with NSCLC, melanoma, or renal cell cancer [22], indicating that the genetic background of cancer patients might determine the clinical responses to anti-PD-1 and anti-PD-L1 treatments. The gene discussed is PDCD1; the disease is renal cell adenocarcinoma.